Charles River Laboratories International, Inc. is a medical research company that provides services to help pharmaceutical and biotechnology companies with drug discovery and development. It operates as a contract research organization, a key part of the healthcare industry. The company currently has a market capitalization of approximately $8.78 billion.
On April 14, 2026, an analyst from RBC Capital set a new price target for Charles River Laboratories International at $215.00. This represents a potential upside of about 20.56% from the stock's price of $178.34 at the time. As highlighted by TheFly, RBC Capital also began its coverage with an "Outperform" rating, suggesting the stock may perform better than the overall market.
This positive outlook is shared by other analysts. Based on a report from Marketbeat, Charles River Laboratories International has an average recommendation of "Moderate Buy" from fifteen firms. The consensus twelve-month price target among these analysts is $206.15. Of the analysts covering Charles River Laboratories International, ten have assigned a buy rating, four a hold, and one a sell.
However, analyst opinions are not all the same. Bank of America upgraded its rating on Charles River Laboratories International from "neutral" to "buy" and set a $225.00 price objective. In contrast, Weiss Ratings maintained its "sell" rating on the shares. Additionally, Barclays lowered its price objective for the company, showing a range of views on its future performance.
Large institutional investors are also making moves. Massachusetts Financial Services Co. acquired a new position of nearly 885,000 shares, valued at around $176.48 million. Furthermore, Vanguard Group Inc. increased its holdings by 0.5%, adding 28,000 shares to its position, which is now valued at approximately $913.69 million.
